New drug AST-201 targets Hard-to-Treat cancers in first human trial
Disease control
Recruiting now
This early-stage study tests a new drug called AST-201 in about 70 adults with advanced solid tumors that have a specific protein called GPC3. The main goal is to check the drug's safety and find the best dose. Researchers will also look at how the drug moves through the body and…
Phase: PHASE1 • Sponsor: Aptamer Sciences, Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC